MicroRNAs associated with chronic kidney disease in the general population and high-risk subgroups: protocol for a systematic review and meta-analysis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE
    • Publication Information:
      Original Publication: [London] : BMJ Publishing Group Ltd, 2011-
    • Subject Terms:
      MicroRNAs* ; Renal Insufficiency, Chronic*/diagnosis ; Renal Insufficiency, Chronic*/epidemiology ; Renal Insufficiency, Chronic*/genetics; Adult ; Biomarkers ; Female ; Glomerular Filtration Rate ; Humans ; Male ; Meta-Analysis as Topic ; Review Literature as Topic ; Systematic Reviews as Topic
    • Abstract:
      Introduction: Chronic kidney disease (CKD) is a significant health and economic burden, owing to its ever-increasing global prevalence. Due to the limitations in the current diagnostic methods, CKD is frequently diagnosed at advanced stages, where there is an increased risk of cardiovascular complications and end-stage kidney disease. As such, there has been considerable interest in microRNAs (miRNAs) as potential markers for CKD detection. This review seeks to identify all miRNAs associated with CKD and/or markers of kidney function or kidney damage in the general population and high-risk subgroups, and explore their expression profiles in these populations.
      Methods and Analysis: A systematic search of published literature will be conducted for observational studies that report on miRNAs associated with CKD or kidney function or kidney damage markers (serum creatinine and cystatin C, estimated glomerular filtration rate and urinary albumin excretion) in adult humans. The electronic database search will be restricted to English and French publications up to 31 October 2021. Two investigators will independently screen and identify studies for inclusion, as well as extract data from eligible studies. Risk-of-bias and methodological quality will be assessed by the Newcastle-Ottawa Quality Assessment Scale for observational studies and Grading of Recommendations Assessment, Development and Evaluation tools. Appropriate meta-analytic techniques will be used to pool estimates from studies with similar miRNAs, overall and by major characteristics, including by country or region, sample size, gender and risk-of-bias score. Heterogeneity of the estimates across studies will be quantified and publication bias investigated. This protocol is reported according to Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols 2015 guidelines.
      Ethics and Dissemination: This study design does not require formal ethical clearance and findings will be published in a peer-reviewed journal.
      Conclusion: This review will provide the expression pattern of miRNAs associated with CKD. This will allow for further research into the identified miRNAs, which could later be used as biomarkers for prediction and early detection of CKD, monitoring of disease progression to advanced stages and as potential therapeutic targets.
      Prospero Registration Number: CRD42021270028.
      Competing Interests: Competing interests: None declared.
      (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
    • References:
      Int J Mol Sci. 2017 Aug 04;18(8):. (PMID: 28777303)
      Eur J Epidemiol. 2010 Sep;25(9):603-5. (PMID: 20652370)
      Kidney Int. 2012 Apr;81(7):617-27. (PMID: 22237749)
      Sci Rep. 2019 Mar 14;9(1):4477. (PMID: 30872798)
      JAMA Cardiol. 2017 Mar 1;2(3):314-318. (PMID: 28002548)
      BMC Nephrol. 2019 Dec 21;20(1):474. (PMID: 31864304)
      Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8. (PMID: 18663219)
      EJIFCC. 2019 Jun 24;30(2):114-127. (PMID: 31263388)
      PLoS Med. 2009 Jul 21;6(7):e1000097. (PMID: 19621072)
      J Am Soc Nephrol. 2015 Oct;26(10):2504-11. (PMID: 25733525)
      Evid Based Complement Alternat Med. 2019 Mar 7;2019:3513179. (PMID: 30984273)
      Curr Opin Nephrol Hypertens. 2017 Nov;26(6):460-466. (PMID: 28806192)
      Nat Rev Nephrol. 2020 May;16(5):251. (PMID: 32144399)
      Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1106-15. (PMID: 25713380)
      Am J Physiol Renal Physiol. 2020 Aug 1;319(2):F335-F344. (PMID: 32657157)
      Lancet. 2020 Feb 29;395(10225):709-733. (PMID: 32061315)
      Cell. 2009 Jan 23;136(2):215-33. (PMID: 19167326)
      Sci Rep. 2017 Jun 2;7(1):2684. (PMID: 28577020)
      Nucleic Acids Res. 2004 Dec 22;32(22):e188. (PMID: 15616155)
      Clin Chem. 2015 Jan;61(1):56-63. (PMID: 25391989)
      Carcinogenesis. 2019 Mar 12;40(1):61-69. (PMID: 30321299)
      Lancet. 2012 Nov 10;380(9854):1662-73. (PMID: 23013602)
      Exp Mol Pathol. 2013 Feb;94(1):65-72. (PMID: 23085312)
      J Clin Epidemiol. 2011 Apr;64(4):383-94. (PMID: 21195583)
      Nat Commun. 2019 May 13;10(1):2145. (PMID: 31086184)
      Environ Health Perspect. 2015 May;123(5):399-411. (PMID: 25616258)
      Acta Diabetol. 2019 Jan;56(1):55-65. (PMID: 30167868)
      Am J Hypertens. 2020 May 21;33(6):505-513. (PMID: 32115655)
    • Contributed Indexing:
      Keywords: chronic renal failure*; end stage renal failure*; genetics*
    • Accession Number:
      0 (Biomarkers)
      0 (MicroRNAs)
    • Publication Date:
      Date Created: 20220217 Date Completed: 20220420 Latest Revision: 20220501
    • Publication Date:
      20221213
    • Accession Number:
      PMC8852766
    • Accession Number:
      10.1136/bmjopen-2021-057500
    • Accession Number:
      35173010